Trial Profile
A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Pyrotinib (Primary)
- Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Salivary gland cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hengrui Therapeutics; Jiangsu Hengrui Medicine Co.
- 28 Jan 2021 Planned End Date changed from 1 Mar 2021 to 1 Jun 2021.
- 28 Jan 2021 Planned primary completion date changed from 30 Sep 2020 to 1 May 2021.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology